Free Trial

Analysts Set Cardlytics, Inc. (NASDAQ:CDLX) PT at $5.20

Cardlytics logo with Business Services background

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) has earned a consensus recommendation of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $5.20.

A number of analysts recently commented on the company. Evercore ISI dropped their price target on Cardlytics from $4.00 to $3.00 and set an "in-line" rating on the stock in a report on Thursday, March 13th. Lake Street Capital dropped their price objective on Cardlytics from $3.00 to $2.50 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Cardlytics in a research note on Thursday, March 13th.

Read Our Latest Stock Report on Cardlytics

Insider Transactions at Cardlytics

In related news, CFO Alexis Desieno sold 24,778 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $84,245.20. Following the completion of the transaction, the chief financial officer now directly owns 140,948 shares in the company, valued at $479,223.20. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Amit Gupta sold 46,857 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $159,313.80. Following the completion of the transaction, the chief executive officer now owns 418,637 shares in the company, valued at $1,423,365.80. This represents a 10.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 71,938 shares of company stock valued at $244,017. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cardlytics

A number of large investors have recently added to or reduced their stakes in CDLX. Tallon Kerry Patrick bought a new position in shares of Cardlytics during the 4th quarter valued at about $37,000. ProShare Advisors LLC bought a new stake in shares of Cardlytics in the 4th quarter worth approximately $43,000. Virtu Financial LLC bought a new stake in shares of Cardlytics in the 4th quarter worth approximately $62,000. Intech Investment Management LLC boosted its stake in shares of Cardlytics by 31.3% in the 4th quarter. Intech Investment Management LLC now owns 19,310 shares of the company's stock valued at $72,000 after purchasing an additional 4,607 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Cardlytics by 38.2% in the 4th quarter. SG Americas Securities LLC now owns 19,490 shares of the company's stock valued at $72,000 after purchasing an additional 5,392 shares in the last quarter. Hedge funds and other institutional investors own 68.10% of the company's stock.

Cardlytics Stock Down 5.1%

Cardlytics stock traded down $0.11 during trading on Friday, hitting $1.96. 575,227 shares of the company were exchanged, compared to its average volume of 985,338. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The business's 50 day moving average is $1.80 and its 200 day moving average is $2.94. Cardlytics has a 52 week low of $1.22 and a 52 week high of $9.85. The company has a market capitalization of $102.64 million, a P/E ratio of -0.32 and a beta of 1.30.

About Cardlytics

(Get Free Report

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

See Also

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Should You Invest $1,000 in Cardlytics Right Now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress Is POURING Into This Stock
The Hottest AI Stock You Haven’t Bought Yet
This $13 Trillion Energy Breakthrough Will Make Millionaires

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines